Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

Hanine El Haddad; Anne-Marie Chaftari; Ray Hachem; Majd Michael; Ying Jiang; Ammar Yousif; Sammy Raad; Mary Jordan; Patrick Chaftari; Issam Raad

doi:10.1038/s41598-018-19616-3

Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia

Sci Rep. 2018 Jan 18;8(1):1099. doi: 10.1038/s41598-018-19616-3.

Authors

Affiliations

¹ Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA. achaftar@mdanderson.org.
³ Emergency Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

In this analysis, we identified febrile cancer patients with documented infections or neutropenia, whose procalcitonin levels are low at baseline or decrease on antibiotics. These patients had similar outcomes in terms of mortality and relapse of infection regardless of the duration of antimicrobial therapy (less or more than 7 days).